ES2415029A8 - Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24. - Google Patents

Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24. Download PDF

Info

Publication number
ES2415029A8
ES2415029A8 ES201390020A ES201390020A ES2415029A8 ES 2415029 A8 ES2415029 A8 ES 2415029A8 ES 201390020 A ES201390020 A ES 201390020A ES 201390020 A ES201390020 A ES 201390020A ES 2415029 A8 ES2415029 A8 ES 2415029A8
Authority
ES
Spain
Prior art keywords
antibody
amplify
elimination
inhibit
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES201390020A
Other languages
English (en)
Other versions
ES2415029R1 (es
ES2415029A2 (es
Inventor
Oleg Iliich Epshtein
Sergey Alexandrovich Tarasov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES2415029A2 publication Critical patent/ES2415029A2/es
Publication of ES2415029A8 publication Critical patent/ES2415029A8/es
Publication of ES2415029R1 publication Critical patent/ES2415029R1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24. La presente invención se refiere a una composición farmacéutica, que comprende una forma activada-potenciada de un anticuerpo contra el receptor CD4 y al uso de dicho anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24.
ES201390020A 2010-08-06 2011-07-15 Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24. Pending ES2415029R1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010133046 2010-08-06
RU2010133046/15A RU2517084C2 (ru) 2010-08-06 2010-08-06 Способ и средство для ингибирования продукции или усиления элиминации белка р24
PCT/IB2011/002355 WO2012017322A2 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein

Publications (3)

Publication Number Publication Date
ES2415029A2 ES2415029A2 (es) 2013-07-23
ES2415029A8 true ES2415029A8 (es) 2013-09-16
ES2415029R1 ES2415029R1 (es) 2013-09-17

Family

ID=44899160

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201390020A Pending ES2415029R1 (es) 2010-08-06 2011-07-15 Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.

Country Status (16)

Country Link
US (2) US20120263726A1 (es)
JP (1) JP2013535483A (es)
CN (1) CN103179987A (es)
AU (1) AU2011287286A1 (es)
CA (1) CA2807523A1 (es)
DE (1) DE112011102639T5 (es)
EA (1) EA029791B1 (es)
ES (1) ES2415029R1 (es)
GB (1) GB2496356A (es)
IT (1) ITTO20110636A1 (es)
MX (1) MX2013001450A (es)
PH (1) PH12013500233A1 (es)
RU (1) RU2517084C2 (es)
SG (1) SG187735A1 (es)
UA (1) UA112752C2 (es)
WO (1) WO2012017322A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
EA030566B1 (ru) 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
CA2805963A1 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2603623C2 (ru) * 2014-06-06 2016-11-27 Олег Ильич Эпштейн Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
NZ334941A (en) * 1996-10-10 2000-11-24 Probe Internat Methods for treating infections using proteins which induce an immune response in one animal species but not in another
AU6941000A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
JPWO2004002511A1 (ja) * 2002-06-28 2005-10-27 扶桑薬品工業株式会社 抗ｈｉｖ剤
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
EP1543166A4 (en) * 2002-09-27 2009-10-28 Genentech Inc SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME
CA2518965C (en) 2003-03-14 2018-10-30 Nutrition Research Inc. Homeopathic formulations useful for treating pain and/or inflammmation
RU2393873C2 (ru) * 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
RU2315058C1 (ru) * 2006-09-27 2008-01-20 Институт органической химии Уфимского научного центра РАН Гликопептид глицирризиновой кислоты с глицил-l-фенилаланином, проявляющий анти-вич-1 активность
US20120263725A1 (en) * 2010-08-06 2012-10-18 Epshtein Oleg Iiiich Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV

Also Published As

Publication number Publication date
CN103179987A (zh) 2013-06-26
DE112011102639T5 (de) 2013-10-02
WO2012017322A3 (en) 2012-04-19
RU2010133046A (ru) 2012-02-20
GB201303865D0 (en) 2013-04-17
EA029791B1 (ru) 2018-05-31
CA2807523A1 (en) 2012-02-09
ES2415029R1 (es) 2013-09-17
RU2517084C2 (ru) 2014-05-27
JP2013535483A (ja) 2013-09-12
ITTO20110636A1 (it) 2012-02-07
PH12013500233A1 (en) 2017-08-23
WO2012017322A2 (en) 2012-02-09
MX2013001450A (es) 2013-10-25
US20120263726A1 (en) 2012-10-18
EA201300138A1 (ru) 2014-03-31
SG187735A1 (en) 2013-03-28
ES2415029A2 (es) 2013-07-23
US20130315964A1 (en) 2013-11-28
GB2496356A (en) 2013-05-08
UA112752C2 (uk) 2016-10-25
AU2011287286A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
NI201400032A (es) Piridopirazinas anticancerígenas via la
ECSP10010295A (es) Formulacion de anticuerpo
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
GT201400111A (es) Triazolopiridinas sustituidas
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
HK1221418A1 (zh) 释放修饰药物的水凝胶-连接的前药
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
ECSP11011307A (es) Comprimidos para terapia de combinacion
BR112012028788A2 (pt) fabricação de grânulos sem ativos
DOP2010000331A (es) Formulacion de medicamento solida con liberacion retardada
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
GT201400042A (es) Compuesto de benzotiazolona
HRP20130082A2 (hr) Farmaceutski pripravak za produljeno oslobađanje trimetazidina

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 20150911